Flexiseq(R): Osteoarthritis Patient Survey Validates Clinical Success

Pro Bono Bio International Trading Limited's innovative new product, Flexiseq for osteoarthritis, demonstrates good results and patient satisfaction in a recent independent consumer group trial.

Munich, Germany (PRWEB UK) 29 March 2013

Pro Bono Bio welcomes the results from an independent patient survey of its product, Flexiseq conducted by the German product-testing community, Feierabend.de. The survey was performed among the community’s osteoarthritis members capturing their “real-life” experiences of the product and producing results that complement Flexiseq's impressive clinical data.

The key findings on Flexiseq, from the patient group were;

Improved joint mobility: 99% reported that Flexiseq was equal or better than other osteoarthritis products with respect to improving joint stiffness.

Pain relief: 97% of respondents reported that Flexiseq was equal or better than other products with respect to its effects on pain.

Reduced and mild side effects: 94% of respondents reported that Flexiseq was equally or better tolerated than other products.

Easy application: 92% reported Flexiseq was equal or better in terms of ease of use against other treatments for osteoarthritis.

High recommendation: 69% of patients would recommend Flexiseq to a friend after just three weeks of use.

These results are astounding given the range of joints tested which went beyond the knee (the focus of the clinical trials) to include fingers, elbows, wrists, shoulders, ankles and hips.

Mr Michael Earl, seen here collecting a recent award for innovation presented to Flexiseq, commented: “This is a very useful real-life survey with sufferers of osteoarthritis reporting great effectiveness of Flexiseq in treating their conditions. What is exciting is the extensive variety of joints patients have successfully used Flexiseq to treat.”

Flexiseq is an innovative German treatment for the management of pain and stiffness in patients with osteoarthritis. The findings of the “real-world” survey support the results from the clinical trials which demonstrate that Flexiseq is an effective treatment for the pain associated with osteoarthritis. This further justifies the product being awarded “Innovation of 2013” by the Federal Association of German Pharmacists, in recognition of its drug-free approach to managing the long term pain of osteoarthritis and, in turn, avoiding the well documented side effects of common drug treatments.

The full report for the medical community is available from:

http://www.biermann-medizin.de/fachbereiche/orthopaedie/medizin-forschung/arthrose-therapie

or, for the simplified report:

http://www.flexiseq.com (available week commencing April 1 2013)
http://www.flexiseq.com.my (available week commencing April 1 2013)


Contact

Follow us on: Contact's Facebook Contact's Twitter